Tag Archives: Boehringer Ingelheim

EASD: Additional Evidence Showed ABASAGLAR® (insulin glargine) Provided Safety and Efficacy Similar to Lantus®

Secondary analyses evaluated ABASAGLAR® in patients previously treated with Lantus® insulin glargine STOCKHOLM, Sept. 15, 2015 / PRNewswire — Data from secondary analyses of Phase III clinical trials showed that ABASAGLAR® (insulin glargine), Eli Lilly and Company and Boehringer Ingelheim’s biosimilar

Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product

– New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency INDIANAPOLIS and INGELHEIM, Germany, Dec. 20, 2013 / PRNewswire / Asianet-Pakistan – Eli Lilly and Company and Boehringer Ingelheim today announced that the U.S. Food and Drug